Added to YB: 2026-01-19
Pitch date: 2025-11-16
VERA [bullish]
Vera Therapeutics, Inc.
+65.05%
current return
Author Info
No bio for this author
Company Info
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases.
Market Cap
$3.4B
Pitch Price
$28.18
Price Target
N/A
Dividend
N/A
EV/EBITDA
-11.22
P/E
-12.11
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Vera Therapeutics, Inc. - $VERA
VERA: Anti-autoimmune biotech w/ Atacicept for IgAN kidney disease. Phase 3 data shows safe & effective treatment; BLA filed for 2026 launch via accelerated approval. $10B US TAM, targeting 15-25% share = $1.5-2.5B peak revenue. At 5x peak rev multiple, potential multi-bagger vs $1.5B EV.
Read full article (3 min)